EVFM

Evofem Biosciences, Inc. OTC

Healthcare ·Biotechnology ·US · evofem.com

$0.01

Mkt Cap $44.3M

52w Low $0.01 5.1% of range 52w High $0.02

50d MA $0.01 200d MA $0.01

P/E (TTM) 3.1x

EV/EBITDA 32.2x

P/B —

Debt/Equity -0.9x

ROE -0.5%

P/FCF -0.6x

RSI (14) —

ATR (14) —

Beta -1.29

50d MA $0.01

200d MA $0.01

Avg Volume 157.9K

About

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia tracho…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 11, 2026	AMC	—	-0.03	—	0.01	+0.0%	+5.7%	+0.0%	+1.1%	+1.1%	+3.4%	+1.1%	—
Nov 13, 2025	AMC	—	-0.01	—	0.01	+0.0%	-10.0%	-8.0%	+0.0%	-1.0%	-4.0%	+11.0%	—
Aug 14, 2025	AMC	—	-0.02	—	0.01	+1.0%	-3.1%	-5.2%	+2.5%	+0.0%	+0.0%	+56.2%	—
May 15, 2025	AMC	—	0.00	—	0.01	+0.7%	+0.7%	+1.8%	-1.5%	+2.9%	+9.5%	+1.8%	—
Mar 24, 2025	AMC	—	-0.03	—	0.01	+4.7%	-3.2%	+5.9%	+10.4%	+10.4%	-0.9%	+0.2%	—
Nov 14, 2024	AMC	—	-0.02	—	0.01	+30.7%	-1.5%	-1.5%	-0.5%	+0.5%	+0.4%	-6.5%	—
Aug 14, 2024	AMC	—	0.00	—	0.01	+0.0%	+0.0%	-5.0%	-5.0%	-2.0%	-3.0%	-9.0%	—
May 15, 2024	AMC	—	-0.16	—	0.02	+3.2%	+12.3%	-6.5%	-7.7%	-10.3%	-16.9%	-16.1%	—
Mar 27, 2024	AMC	-0.61	-0.44	+27.9%	0.03	+11.5%	-7.3%	-21.5%	-19.2%	-19.2%	-20.0%	-35.6%	—
Nov 14, 2023	AMC	-7.50	0.10	+101.3%	0.07	+14.3%	+0.0%	-10.0%	+0.0%	-2.9%	+4.3%	+21.4%	—
Aug 14, 2023	AMC	-10.00	-5.43	+45.7%	0.37	-28.4%	-13.5%	-24.3%	-40.5%	-55.1%	-48.9%	-55.9%	—
Jun 16, 2023	AMC	-15.00	-1.85	+87.7%	1.00	+28.0%	+7.0%	+0.0%	+0.0%	-10.0%	-23.9%	-36.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Oct 13	Stifel	Downgrade	Buy → Hold	—	$12.13	$12.50	+3.1%	-5.2%	-6.2%	-10.3%	-17.6%	-17.6%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$51.63	$51.63	+0.0%	-1.9%	-7.3%	-5.6%	+8.2%	+1.7%
Jul 15	Morgan Stanley	Maintains	Underweight → Underweight	—	$133.75	$130.00	-2.8%	-17.9%	-17.9%	-24.5%	-22.6%	-6.5%
Jun 2	Laidlaw & Co.	Maintains	Buy → Buy	—	$43.38	$43.75	+0.9%	-0.9%	+14.7%	+3.7%	+3.5%	+5.5%
May 25	Piper Sandler	Maintains	Overweight → Overweight	—	$45.13	$45.63	+1.1%	-0.3%	-3.9%	-3.3%	-0.3%	-3.9%
May 11	Morgan Stanley	Maintains	Underweight → Underweight	—	$140.00	$137.50	-1.8%	-4.5%	+8.0%	+1.8%	-8.0%	+0.9%
May 10	Morgan Stanley	Maintains	Underweight → Underweight	—	$151.25	$153.75	+1.7%	-7.4%	-11.6%	+0.0%	-5.8%	-14.9%
Apr 12	Morgan Stanley	Maintains	Underweight → Underweight	—	$465.00	$468.75	+0.8%	-2.4%	-5.2%	-8.9%	-8.5%	-6.9%
Mar 4	Morgan Stanley	Maintains	Underweight → Underweight	—	$918.75	$853.13	-7.1%	-10.2%	-20.4%	-20.0%	-18.4%	-20.0%
Nov 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1246.88	$975.00	-21.8%	-15.6%	-18.9%	-27.8%	-30.8%	-27.7%
Oct 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1342.50	$1350.00	+0.6%	-1.0%	-2.5%	-2.0%	-2.2%	-3.9%
Oct 14	Morgan Stanley	Downgrade	Equal Weight → Underweight	—	$1406.25	$1387.50	-1.3%	-4.4%	-7.6%	-5.9%	-5.3%	-4.5%
Aug 12	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$1586.25	$1539.38	-3.0%	-9.8%	-16.0%	-20.4%	-19.6%	-19.1%
Jun 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1621.88	$1848.75	+14.0%	+19.1%	+16.8%	+15.6%	+21.4%	+44.5%
Mar 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4275.00	$4181.25	-2.2%	-3.1%	-0.4%	+18.4%	+25.9%	+25.4%
Oct 2	Stifel	Maintains	Buy → Buy	—	$4481.25	$4256.25	-5.0%	+7.1%	+13.4%	+13.0%	+18.8%	+21.8%
Aug 20	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$6300.00	$6206.25	-1.5%	-4.5%	-9.2%	-8.9%	-4.8%	-7.4%
Jun 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6468.75	$6562.50	+1.4%	-2.3%	-8.8%	-16.2%	-15.9%	-14.5%
Jun 8	Piper Sandler	Maintains	Overweight → Overweight	—	$6206.25	$6553.13	+5.6%	+4.2%	+1.8%	-5.0%	-12.7%	-12.4%
May 27	Oppenheimer	Maintains	Outperform → Outperform	—	$10856.25	$10706.25	-1.4%	+2.4%	-4.5%	-5.7%	-12.6%	-19.5%
Dec 11	H.C. Wainwright	Maintains	Buy → Buy	—	$11812.50	$12187.50	+3.2%	+0.5%	-1.4%	-2.7%	-7.8%	-8.4%
Sep 26	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$7593.75	$8362.50	+10.1%	+9.9%	+5.2%	+0.0%	+3.0%	-2.2%
Jun 27	RBC Capital	Maintains	Outperform → Outperform	—	$5925.00	$6056.25	+2.2%	-0.3%	-5.1%	-14.2%	-22.2%	-23.1%
Jun 18	Oppenheimer	Maintains	Outperform → Outperform	—	$6150.00	$6843.75	+11.3%	+4.0%	+0.6%	+6.7%	+1.2%	+5.2%
Mar 19	H.C. Wainwright	Maintains	Buy → Buy	—	$12993.75	$12975.00	-0.1%	+2.3%	+1.4%	-2.7%	-2.0%	+13.3%

Recent Filings

8-K · 1.01 !! High

Evofem Biosciences, Inc. -- 8-K 1.01: Material Agreement

Evofem Biosciences entered into a material agreement with Clovis Davis Pharmaceuticals, though specific terms remain undisclosed in this filing.

Apr 30

8-K · 1.01 !! High

Unknown — 8-K 1.01: Material Agreement

Evofem Biosciences entered a material agreement that could affect its financial position and operations, making this filing important for investors to understand potential partnership, financing, or commercial impacts on the company's future performance and stock value.

Apr 16

8-K · 1.02 !! High

Unknown — 8-K 1.02: Material Agreement Terminated

Evofem terminated a material agreement with Windtree Therapeutics, likely eliminating expected revenue or partnership benefits and signaling strategic shift or financial constraints for EVFM shareholders.

Mar 19

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Evofem Biosciences disclosed non-material information under Regulation FD that won't impact legal liability, suggesting routine updates unlikely to significantly move the stock.

Mar 11

Data updated apr 28, 2026 8:03am · Source: massive.com